
|Videos|December 27, 2022
RCC Trial Review: Checkmate 9ER
Author(s)Rana R. McKay, MD
Dr McKay reviews key trial data from the CheckMate 9ER trial including eligible patient populations, study design, and safety/efficacy data.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5







































